124 related articles for article (PubMed ID: 2188766)
1. Chronic vasodilator therapy with flosequinan in congestive heart failure.
Haas GJ; Binkley PE; Leier CV
Clin Cardiol; 1990 Jun; 13(6):414-20. PubMed ID: 2188766
[TBL] [Abstract][Full Text] [Related]
2. Flosequinan, a new vasodilator: systemic and coronary hemodynamics and neuroendocrine effects in congestive heart failure.
Cavero PG; De Marco T; Kwasman M; Lau D; Liu M; Chatterjee K
J Am Coll Cardiol; 1992 Dec; 20(7):1542-8. PubMed ID: 1452928
[TBL] [Abstract][Full Text] [Related]
3. Effect of flosequinan on exercise capacity and cardiac function in patients with chronic mild heart failure: a double-blind placebo-controlled study.
Hori M; Sato H; Ozaki H; Inoue M; Naka M; Fukunami M; Fukushima M; Kunisada K
Heart Vessels; 1992; 7(3):133-40. PubMed ID: 1500398
[TBL] [Abstract][Full Text] [Related]
4. Cumulative hemodynamic response to short-term treatment with flosequinan (BTS 49465), a new direct-acting vasodilator drug, in severe chronic congestive heart failure.
Kessler PD; Packer M; Medina N; Yushak M
J Cardiovasc Pharmacol; 1988 Jul; 12(1):6-11. PubMed ID: 2459536
[TBL] [Abstract][Full Text] [Related]
5. Sustained hemodynamic response to flosequinan in patients with heart failure receiving angiotensin-converting enzyme inhibitors.
Gottlieb SS; Kukin ML; Penn J; Fisher ML; Cines M; Medina N; Yushak M; Taylor M; Packer M
J Am Coll Cardiol; 1993 Oct; 22(4):963-7. PubMed ID: 8409070
[TBL] [Abstract][Full Text] [Related]
6. Can further benefit be achieved by adding flosequinan to patients with congestive heart failure who remain symptomatic on diuretic, digoxin, and an angiotensin converting enzyme inhibitor? Results of the flosequinan-ACE inhibitor trial (FACET).
Massie BM; Berk MR; Brozena SC; Elkayam U; Plehn JF; Kukin ML; Packer M; Murphy BE; Neuberg GW; Steingart RM
Circulation; 1993 Aug; 88(2):492-501. PubMed ID: 8339411
[TBL] [Abstract][Full Text] [Related]
7. Flosequinan in chronic heart failure: how is exercise capacity improved?
Banning AP; Ramsey MW; Jones EA; Evans W; Carolan G; Jones CH; Henderson AH
Eur J Clin Pharmacol; 1996; 51(2):133-8. PubMed ID: 8911877
[TBL] [Abstract][Full Text] [Related]
8. Double-blind, placebo-controlled study of the efficacy of flosequinan in patients with chronic heart failure. Principal Investigators of the REFLECT Study.
Packer M; Narahara KA; Elkayam U; Sullivan JM; Pearle DL; Massie BM; Creager MA
J Am Coll Cardiol; 1993 Jul; 22(1):65-72. PubMed ID: 8509565
[TBL] [Abstract][Full Text] [Related]
9. Effect of flosequinan on exercise capacity and symptoms in severe heart failure.
Elborn JS; Stanford CF; Nicholls DP
Br Heart J; 1989 Apr; 61(4):331-5. PubMed ID: 2653391
[TBL] [Abstract][Full Text] [Related]
10. A double-blind, parallel-group comparison of flosequinan and enalapril in the treatment of chronic heart failure.
Silke B; Tennet H; Fischer-Hansen J; Keller N; Heikkila J; Salminen K
Eur Heart J; 1992 Aug; 13(8):1092-100. PubMed ID: 1505560
[TBL] [Abstract][Full Text] [Related]
11. Acute and chronic effects of flosequinan on resting and exercise haemodynamics in congestive heart failure.
Thomas P; O'Gorman DJ; Sheridan DJ
Br J Clin Pharmacol; 1993 Dec; 36(6):539-46. PubMed ID: 12959270
[TBL] [Abstract][Full Text] [Related]
12. Central and regional hemodynamic effects of flosequinan for congestive heart failure.
Haas GJ; Binkley PF; Carpenter JA; Leier CV
Am J Cardiol; 1989 Jun; 63(18):1354-9. PubMed ID: 2658526
[TBL] [Abstract][Full Text] [Related]
13. Importance of assessing changes in ventricular response to atrial fibrillation during evaluation of new heart failure therapies: experience from trials of flosequinan.
Massie BM; Shah NB; Pitt B; Packer M
Am Heart J; 1996 Jul; 132(1 Pt 1):130-6. PubMed ID: 8701855
[TBL] [Abstract][Full Text] [Related]
14. Flosequinan in heart failure: acute haemodynamic and longer term symptomatic effects.
Cowley AJ; Wynne RD; Stainer K; Fullwood L; Rowley JM; Hampton JR
BMJ; 1988 Jul; 297(6642):169-73. PubMed ID: 3044507
[TBL] [Abstract][Full Text] [Related]
15. Influence of flosequinan on autonomic tone in congestive heart failure: implications for the mechanism of the positive chronotropic effect and survival influence of long-term vasodilator administration.
Binkley PF; Nunziata E; Cody RJ
Am Heart J; 1994 Dec; 128(6 Pt 1):1147-56. PubMed ID: 7985595
[TBL] [Abstract][Full Text] [Related]
16. Long-Term Effects of Flosequinan on the Morbidity and Mortality of Patients With Severe Chronic Heart Failure: Primary Results of the PROFILE Trial After 24 Years.
Packer M; Pitt B; Rouleau JL; Swedberg K; DeMets DL; Fisher L
JACC Heart Fail; 2017 Jun; 5(6):399-407. PubMed ID: 28501522
[TBL] [Abstract][Full Text] [Related]
17. A non-invasive evaluation of flosequinan on haemodynamics and exercise capacity in chronic congestive heart failure.
Motro M; Freimark D; Feinberg MS; Wynne RD; King C; Schneeweiss A
Int J Clin Pharmacol Res; 1993; 13(3):143-9. PubMed ID: 8225697
[TBL] [Abstract][Full Text] [Related]
18. Long-term vasodilator treatment with flosequinan does not lead to hemodynamic tolerance or neurohormonal activation in severe heart failure.
Bartels GL; Remme WJ; Look MP; Kruijssen DA
J Card Fail; 1995 Mar; 1(2):117-25. PubMed ID: 9420641
[TBL] [Abstract][Full Text] [Related]
19. Clinical efficacy of flosequinan in heart failure.
Cowley AJ
Am Heart J; 1991 Mar; 121(3 Pt 1):983-8. PubMed ID: 2000777
[TBL] [Abstract][Full Text] [Related]
20. Acute and long-term effects of flosequinan in patients with chronic cardiac failure.
Marchionni N; Moschi G; Di Bari M; Burgisser C; Fumagalli S; Boncinelli L; Tarantini F; Ferrucci L
Am Heart J; 1993 Jul; 126(1):147-54. PubMed ID: 8322657
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
